Accessibility Menu
Iqvia Holdings logo

Iqvia Holdings(NYSE) IQV

Market Cap$39.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)+465%
5 Year-4%
1 Year+24%
1 Month+23%
$235.57
-0.93%
-2.22Today
Iqvia Holdings last closing stock price
MetricPriceDate
Last closeUSD 237.792026-07-30
Iqvia Holdings stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+14.7%USD 207.322026-07-23
1 month+23.07%USD 193.222026-06-30
3 month+50.72%USD 157.772026-05-01
Year to date+5.49%USD 225.412025-12-31
1 year+24.15%USD 191.542025-07-30
3 year+6.27%USD 223.762023-07-31
5 year-4%USD 247.702021-07-30
Since inception+464.69%USD 42.112013-05-09

Iqvia Holdings Financials at a Glance

Market Cap

$39.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$16.98B

Net Income (TTM)

$1.38B

EPS (TTM)

$8.06

P/E Ratio

29.50

Dividend

$0.00

Beta (Volatility)

1.13 (Average)

Price

$235.57

Volume

702,281.918

Open

$236.97

Previous Close

$237.79

Daily Range

$230.93 - $237.94

52-Week Range

$154.50 - $251.36

Estimated Earnings Date

Oct 27, 2026

IQV: Motley Fool Moneyball Superscore

72

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Iqvia Holdings

IQVIA helps drug makers and healthcare groups use data to develop new medicines. It manages clinical trials to test if new treatments are safe and effective. The company also provides software that helps doctors and pharmacies track health trends.

What IQVIA Does

  • Research & Development Solutions: Manages clinical trials, patient recruitment, and lab services for pharmaceutical companies.
  • Technology & Analytics Solutions: Provides cloud-based software, health data analytics, and consulting services to improve medical decisions.
  • Contract Sales & Medical Solutions: Offers specialized staff to help healthcare providers learn about new drugs and patient support programs.

Strategic Moves and Growth

  • Maintained a strategic collaboration with HealthCore, Inc. to expand data capabilities.
  • Launched Healthcare-grade AI to help clients find patient patterns and speed up drug development.
  • Expanded the Avacare Clinical Research Network to manage over 180 investigators across nearly 50 locations.
  • Introduced the IQVIA Health Data Catalog to help researchers find and use real-world health information in over 100 countries.

What Makes IQVIA Different

The company maintains a massive database with over 1.2 billion non-identified patient records to provide deep medical insights. Its global reach spans 100 countries, allowing it to track 90% of global pharmaceutical sales.

The Recent Financial Record

  • Revenue reached $4.4 billion in Q4 2025, up 10.3% from the previous year.
  • Operating income rose to $732 million in Q4 2025, a 16.9% increase year-over-year.
  • Net income grew to $514 million in Q4 2025, up 17.6% from Q4 2024.
  • Free cash flow was $561 million in Q4 2025, down 22.2% from $721 million in Q4 2024.
  • The company employed approximately 93,000 people as of late 2025, up from 89,000 previously reported.

Evolution and Future Path

IQVIA has transitioned from a traditional research firm into a technology-driven leader in human data science. Its integration of advanced analytics with clinical trial management provides a specialized platform for the global life sciences industry.

AI Generated • Apr 19, 2026

Industry

Life Sciences Tools and Services

Employees

94,000

CEO

Ari Bousbib, MBA

Headquarters

Durham, NC 27703, US

IQV Financials

Key Financial Metrics (TTM)

Gross Margin

26.23%

Operating Margin

13.57%

Net Income Margin

8.10%

Return on Equity

21.95%

Return on Capital

10.09%

Return on Assets

4.60%

Earnings Yield

3.39%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$39.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

164.60M

Volume

702.28K

Avg. Volume

1.67M

Financials (TTM)

Gross Profit

$4.46B

Operating Income

$2.31B

EBITDA

$3.53B

Operating Cash Flow

$2.88B

Capital Expenditure

$119.00M

Free Cash Flow

$2.99B

Cash & ST Invst.

$2.08B

Total Debt

$16.24B

Iqvia Holdings Performance Analysis

Iqvia Holdings annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 14,420,000,0003.9%
20232023-12-31USD 14,963,000,0003.8%
20242024-12-31USD 15,405,000,0003.0%
20252025-12-31USD 16,304,000,0005.8%
Iqvia Holdings sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-302.1%
Q42025-12-316.4%
Q12026-03-31-4.9%
Q22026-06-305.2%
Iqvia Holdings annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 5.7215.5%
20232023-12-31USD 7.2927.3%
20242024-12-31USD 7.492.7%
20252025-12-31USD 7.844.7%
Iqvia Holdings sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3025.3%
Q42025-12-3154.9%
Q12026-03-31-46.2%
Q22026-06-30-5.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$4.37B

+8.7%

Gross Profit

$1.44B

+8.5%

Gross Margin

32.85%

N/A

Market Cap

$39.14BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$420.86K

N/A

Employees

93,000

N/A

Net Income

$256.00M

-3.8%

EBITDA

$790.00M

+1.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$2.08B

-4.9%

Total Debt

$16.24B

+3.4%

Accounts Receivable

$3.39B

-0.6%

Inventory

$0.00

N/A

Long Term Debt

$13.95B

-3.1%

Short Term Debt

$2.29B

+74.7%

Return on Assets

4.60%

N/A

Return on Invested Capital

10.94%

N/A

Free Cash Flow

$741.00M

+153.8%

Operating Cash Flow

$614.00M

+38.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AAgilent Technologies, Inc.
$139.29+0.42%
HLNHaleon plc
$9.88-2.32%
HUMHumana Inc.
$364.84-0.50%
ALCAlcon Inc.
$68.86-1.08%

Trending Stocks

Symbol / CompanyPricePrice Chg
AMZNAmazon
$272.01+0.16%
AAPLApple
$305.40-0.08%
FCUVFocus Universal
$13.95+6.42%
NVDANvidia
$200.34+0.03%

Questions About IQV

What is the current price of Iqvia Holdings?

Iqvia Holdings is trading at $235.06 per share.

What is the 52-week range for Iqvia Holdings?

Over the past 52 weeks, Iqvia Holdings has traded between $154.50 and $251.36.

How much debt does Iqvia Holdings have?

As of the most recent reporting period, Iqvia Holdings reported total debt of $16.24B.

How much cash does Iqvia Holdings have on hand?

Iqvia Holdings reported $1.91B in cash and cash equivalents in its most recent financial results.

What is Iqvia Holdings’s dividend yield?

Iqvia Holdings does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.